Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Antibe Partnership to Accelerate Drug Pipeline
View:
Post by mstrmnd on Nov 02, 2021 10:12pm

Antibe Partnership to Accelerate Drug Pipeline

Based on quality of data from existing studies, I would not be surprised if Antibe partnered with Big Pharma earlier than expected to accelerate entire drug pipeline

Antibe can conduct multiple Phase 3 clinical trials with their pipeline simultaneously with a pharma partner - Antibe took 7 years to get ATB-346 here, with a pharma partner, all 4 of their top patents can be accelerated into their respective markets

GLTA
Comment by MrMugsy on Nov 02, 2021 10:58pm
That certainly is one potential angle and I'd welcome it. But - I see a required path in order to open that up to us. 346(acute) seems to be straight forward. 352(acute) to also follow suit  - but -  we don't know the specific purpose intended for that drug (yet). Then - the rest of the pipeline is what we'd call "long term" or chronic type indications (for the ...more  
Comment by mstrmnd on Nov 03, 2021 12:40am
If you have an IND/DIN for oral treatment of acute pain, it's natural progression to go to chronic pain thereafter There's absolutely no need to do dose ranging for chronic pain pre-partnership, otherwise could burn through cash when #1 priority IND/DIN is Post-Operative Pain for Otenaproxesul After successful Phase 2 in Post-Operative Pain, Antibe will have very successul efficacy and ...more  
Comment by MrMugsy on Nov 03, 2021 1:31am
If ATE can move acute pain medications to chronic indications (which I get the white-label approach), why have they spent over a million dollars on liver specialists?  Dan says they are prepared to spend more to find an OA solution. Why waste time here ? “The Company is investigating alternative dosing regimens as a potential path forward for chronic indications.” Would this go above and ...more  
Comment by mstrmnd on Nov 03, 2021 9:52am
They need to have clarity that chronic indications are feasible but do not necessarily need to conduct large clinical trials for chronic use in OA until a partnership.  It's best to have as much cash as possible for negotiations and firm up chronic use in cost-effective means.   This is why the position of the company has now entirely changed.  When you're an acute ...more  
Comment by StockingUp21 on Nov 03, 2021 11:00am
crzymnd, if partnerships were happening it would by now before we learned the liver issue. 
Comment by fox7mf on Nov 03, 2021 11:12am
A buyout/takeover right now or soon would not, I believe, get us what most of us want for Antibe. How much could they possibly ask for the pipeline at the moment or in the next 6-12 months?
Comment by mstrmnd on Nov 03, 2021 7:24pm
They are looking to get at least $1B for Otenaproxesul.  This is the entry point for any player to take it.  No point selling less, it's worth more.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities